SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services for pharmaceutical products. It operates through the CDMO and Biopharmaceutical Development and Commercialization business divisions. The CDMO division provides development services from cell line development to early clinical trials, including cell line development, processes, formulations, and analysis methods. The Biopharmaceutical Development and Commercialization division focuses on the development and commercialization of biosimilars and is conducting research and development on various disease fields such as autoimmune diseases, cancer diseases, ophthalmic diseases, and blood diseases. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.